Chairperson
Jeffrey S. Weber, MD, PhD H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida
Faculty
Steven O’Day, MD The Angeles Clinic and Research Institute Santa Monica, California Vernon K. Sondak, MD H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida Jedd D. Wolchok, MD, PhD Memorial Sloan-Kettering Cancer Center New York, New York

6:30 pm	Buffet dinner
7:00 pm	Introduction Jeffrey S. Weber, MD, PhD
7:10 pm	Established immunotherapies for melanoma: A historical perspective and latest advances in adjuvant therapy and metastatic disease management Vernon K. Sondak, MD
7:30 pm	A targeted approach to immunotherapy: Breaking immune tolerance to melanoma Steven O’Day, MD
7:50 pm	Interactive clinical case scenario Minimally progressive disease: When to hold, when to fold Jeffrey S. Weber, MD, PhD
8:15 pm	Interactive clinical case scenario Long-term responders that progress in a single site: When to re-treat, when to resect Jedd D. Wolchok, MD, PhD
8:40 pm	Expanding options: Targeting novel immune regulating costimulatory molecules Jeffrey S. Weber, MD, PhD
8:55 pm	Closing remarks Jeffrey S. Weber, MD, PhD
9:00 pm	Adjourn

Enlisting the Immune System in the Management of Melanoma: Advances and Updates is intended for medical and surgical oncologists, dermatologists, researchers, and other healthcare professionals interested in and/or involved in the care of patients with melanoma.

As the rate at which clinical data is released increases and the number of therapeutic options being examined in clinical trials expands, practicing oncologists and dermatologists providing care for patients with melanoma struggle to stay abreast of these advances. In order for rapid clinical progress to have a direct and immediate impact on patients' lives, the latest findings must be made available in a format where they can be readily applied to practice. Providers require a resource to help them understand the latest advances in melanoma therapy and aid them in translating data into practical concepts in order to maximize clinical outcomes in the care of patients with melanoma.

After successfully completing this educational activity, participants should be able to:

• Identify the settings in which specific immunotherapies are used for the management of melanoma
• Explain the mechanism of immune tolerance and the rationale for immunotherapy in the treatment of melanoma
• Describe clinical data regarding the use of specific immunotherapies in the management of melanoma in terms of associated efficacies, kinetics of response and adverse events so that implementation of these therapies is guided by expected outcomes

Postgraduate Institute for Medicine requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

This educational activity may contain discussion of published or and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Postgraduate Institute for Medicine, PRIME Oncology, and Bristol-Myers Squibb Company do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, PRIME Oncology, or Bristol-Myers Squibb Company. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.